Key Highlights

  • 0.11 stands as the negative consensus EPS estimate in screener data for Biofrontera Inc. (NASDAQ:BFRI), scheduled to release third quarter 2026 results ahead of the opening bell on November 13, 2026.
  • 12.0 million is the USD net product Revenue booked in second-quarter 2026, a 32.9% jump from USD 9.0 million, as gross Margin climbed to 80% from 71% twelve months earlier.
  • 0.6 million is the USD loss for second-quarter 2026, or USD 0.05 a share, compared with USD 5.3 million, or USD 0.57 a share, while adjusted EBITDA improved to negative USD 0.2 million.
  • 13.92 million is the USD market Capitalization in screener data, nano-cap territory, while cash totalled USD 4.7 million at June 30, 2026 and an FDA decision date of September 28, 2026 had been set.

What Canadian Investors Can Watch From Biofrontera Inc. (NASDAQ:BFRI) on November 13, 2026

Biofrontera Inc. is expected to release third quarter 2026 results ahead of the opening bell (BMO) on November 13, 2026. Screener data shows a consensus estimate of USD 0.11 lost per share, a wider shortfall than the USD 0.05 per share posted last quarter. The half-year shortfall was USD 0.44 per share against USD 1.05. Screener data puts market capitalization at USD 13.92 million, a tiny size carrying pronounced Volatility and thin-trading risk. Published coverage showed shares at USD 1.28, within a 52-week band of USD 0.55 to USD 1.40.

The Rationale: Latest Quarter and Management Outlook for Biofrontera Inc. (NASDAQ:BFRI)

During second-quarter 2026, costs for selling and administration declined to USD 9.7 million from USD 10.6 million thanks to reduced litigation fees, while Research and Development spending slid to USD 0.4 million from USD 0.9 million. Net product sales across the first half reached USD 22.1 million, a 25.4% rise from USD 17.6 million, and the loss shrank to USD 5.4 million from USD 9.5 million. Cash consumed by operations dropped to USD 1.7 million from USD 7.2 million. Coverage turned up no numeric outlook; management indicated it sits nearer to breakeven in 2026 since the October 2025 deal with Biofrontera AG lowered Ameluz costs.

Valuation, Liquidity and Risks for Biofrontera Inc. (NASDAQ:BFRI)

Screener data lists Market Value at USD 13.92 million. Cash stood at USD 4.7 million on June 30, 2026, liabilities totalled USD 18.1 million and shareholders' Equity measured USD 6.0 million, down from USD 10.5 million at year-end. Published coverage did not include Debt or share count. The PDUFA date for the superficial form of basal cell carcinoma was September 28, 2026, and no outcome turned up. Price hikes and some early-pulled orders helped lift revenue. Risks cover scarce cash, regulatory results and thin nano-cap trading.

Where Things Stand

Biofrontera Inc. (NASDAQ:BFRI) releases third quarter 2026 results ahead of the opening bell on November 13, 2026, with a consensus EPS estimate of -0.11 and market value of USD 13.92 million in screener data. Second-quarter 2026 brought revenue of USD 12.0 million, an 80% gross margin, plus adjusted EBITDA of negative USD 0.2 million, compared with negative USD 5.1 million a year before. Half-year adjusted EBITDA was negative USD 3.7 million compared with negative USD 9.5 million. Readers should watch whether orders brought forward cool growth, how USD 4.7 million in cash gets deployed, and any news following the September 28, 2026 FDA decision date. This article is informational only and does not constitute Investment advice.